Aptamer Group Announces Director Dealings
The healthcare company has announced changes to its major shareholdings.
The healthcare company has announced changes to its major shareholdings.
The biotechnology company has announced the posting of a circular and notice of a general meeting to shareholders.
The biotechnology company has raised £2 million through a discounted share placing, representing 25% dilution for existing shareholders.
The biotechnology company announces a breakthrough in its efforts to develop a targeted therapy for liver fibrosis using its proprietary Optimer® platform.
The biotechnology company has secured a development and licensing agreement with a major global life sciences firm to create a custom Optimer®-Fc reagent for use in diagnostic kits, providing a new revenue stream.
The biotechnology company has secured a second development programme with a global consumer goods leader, expanding its partnership and potential revenue streams in the personal care market.
The biotechnology company presents new data on its Optimer delivery platform, indicating potential for broad therapeutic application across fibrotic diseases.
The leading developer of synthetic binders has secured new development contracts and licensing deals, signaling continued commercial traction for its Optimer platform.
The biotechnology company has advanced its Alzheimer's disease diagnostic test, adapting it to a widely used hospital format and securing a royalty agreement with a partner.
The biotechnology company has secured a global licensing agreement for its Optimer binders to be used as vaccine adjuvants in the swine health sector, creating a new revenue stream.